Sunshine Lake Pharma Co., Ltd.

Guangdong Oppo Mobile Telecommunications Corp., Ltd.

Vivo Mobile Communication Co., Ltd.

Huawei Digital Power Technologies Co., Ltd.

Yang Liu

Yingjun Zhang

Qingyun Ren

Jianzhou Huang

Jinfeng Xiong

Siegfried Goldmann

Xinchang Liu

Cong Shi

Shukun Wang

Feng Liu

Xin You

Biao Hu

Xue Lin

Zhifu Zou

Guanghua Yan

Jiangsheng Fan

Jiamin Liu

Zhimin Xiong

You Li

Yuxiu Liu

Fangcai Yu

Weishun Liu

Yifeng Wang

This application discloses a handover method and apparatus, a terminal device, and a network device. The handover method includes: receiving a first message sent by a source cell, where the first message is used to instruct a relay terminal to hand over to a target cell, the first message carries target configuration information of the target cell, and the target configuration information includes first configuration information of the relay terminal and second configuration information of data of a remote terminal on a Uu interface, where the remote terminal is a remote terminal of the relay terminal; and accessing the target cell according to the target configuration information.

Handover method and apparatus, terminal device, and network device

Embodiments of the present disclosure provide a secondary node change method, a terminal device, and a network device. The network device can timely know that measurement results of the terminal device meet the secondary node change condition, thereby improving the performance of secondary node change. The secondary node change method includes: receiving, by a master node, first indication information indicating that a secondary node change condition has been met or that a secondary node change process has been initiated by a terminal device; and transmitting, by the master node in response to the first indication information, second indication information to a source secondary node, the second indication information instructing the source secondary node to release a connection towards the terminal device, and/or instructing the source secondary node to terminate data transmission towards the terminal device.

Secondary node change method, terminal device and network device

A fused tricyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. Specifically, the present invention relates to a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variable is as defined in the specification. The present invention also relates to the use of a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.

Fused tricyclic compounds and uses thereof in medicine

This application relates to the field of electronic device technologies, and provides an electronic component with an enclosure frame, a circuit board with an electronic component, and an electronic device, to effectively protect the circuit board from being corroded, thereby prolonging a service life of the electronic device. This application is applied to a charging pile for charging a new energy electric vehicle. An electronic component with an enclosure frame includes an enclosure frame and an electronic component. The enclosure frame defines a cavity that is closed or that has one open end; when the electronic component with an enclosure frame is connected to a circuit board, the enclosure frame and the circuit board can define a cavity that is closed or that has one open end.

Electronic component with enclosure frame, circuit board with electronic component, and electronic device

Provided are a communication method, a terminal device and a network device. The terminal device receives configuration information sent by a network device, the configuration information being used for indicating one or more conditions for the terminal device to report random access-related information. The terminal device sends a successful handover report that does not contain the random access-related information to the network device in response to a random access of the terminal device not satisfying the one or more conditions for reporting the random access-related information.

Communication method and apparatus

A mobile terminal includes a first module and a second module. The first module and the second module are in a folded state or an extended state. The first module is provided with a first antenna radiation branch, the first antenna radiation branch is provided with a first feed point and a first ground point, and the first feed point is electrically connected to a first feed source via a switch. The second module is provided with a second antenna radiation branch, and the second antenna radiation branch is provided with a second feed point and a second ground point. In the case where the first module and the second module are in the folded state, the switch is in the off state, and in the case where the first module and the second module are in the extended state, the switch is in the on state.

Mobile terminal and antenna control method

A fused tetracyclic compound and application thereof in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B. A compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, in medicine, especially as a medicament for the treatment and/or prevention of hepatitis B, wherein each variable is as defined in the specification. 

Fused tetracyclic compounds and uses thereof in medicine

A fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variate is as defined in specification. The compound also includes a Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B. 

Growing community of inventors

Dongguan, China

Yang Liu